Lisata Therapeutics
LSTA
34 hedge funds and large institutions have $5M invested in Lisata Therapeutics in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 4 closing their positions.
1,464% more call options, than puts
Call options by funds: $172K | Put options by funds: $11K
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 33 → 34 (+1)
0.07% more ownership
Funds ownership: 0.97% → 1.04% (+0.07%)
18% less capital invested
Capital invested by funds: $6.13M → $5M (-$1.13M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$413K |
| 2 |
IIA
IPG Investment Advisors
San Diego,
California
|
+$75.5K |
| 3 |
Renaissance Technologies
New York
|
+$63.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$13.5K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$10K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$81.9K |
| 2 |
Two Sigma Investments
New York
|
-$68K |
| 3 |
Two Sigma Advisers
New York
|
-$37.7K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$26.2K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$15.1K |
LSTA Hedge Fund Activity: Q2 2022 in Review
34 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q2 2022, worth a combined $5M — down 18% from $6.13M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LSTA positions and 4 closed out — a net gain of 1 holder — while 9 added to existing stakes and 7 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $413K. The largest seller was BlackRock, cutting an estimated $81.9K.
- 34 institutional investors held Lisata Therapeutics (LSTA) as of Q2 2022, up from 33 in Q1 2022.
- Funds reported $5M of Lisata Therapeutics stock for Q2 2022, down 18% quarter-over-quarter.
- 5 funds opened new Lisata Therapeutics positions in Q2 2022 and 4 closed out, a net change of +1 holder.
- The largest Lisata Therapeutics buyer in Q2 2022 was RA Capital Management, an estimated $413K added.
- The largest Lisata Therapeutics seller in Q2 2022 was BlackRock, an estimated $81.9K sold.
Based on aggregated 13F filings for Q2 2022.